Will hopefully get some clarification what this means in due course. (i.r. from someone that knows what they're talking about, not someone looking at charts)
The effects observed following treatment with the low dose of trofinetide (35 mg/kg twice daily) were less consistent and the magnitude of improvement did not meet pre-specified targets, but there was evidence of a dose response. Given the excellent tolerability profile of trofinetide and the observed dose response profile, there is a clear rationale to study higher doses.
Ann: Trofinetide successful in Phase 2 trial in Fragile X, page-22
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.86 |
Change
0.560(2.90%) |
Mkt cap ! $2.538B | |||
| Open | High | Low | Value | Volume |
| $19.80 | $20.00 | $19.40 | $3.777M | 191.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1060 | $19.83 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.87 | 209 | 1 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |